Table 4. Effects of NR1I2 haplotype and CYP2B6 genotypes on SF -mediated metabolic induction of bupropion hydroxylation.

	CYP2B6 * 6 noncarriers (wild-type) (n = 18)		CYP2B6 * 6 carriers (n = 15)		pd
	TGT Noncarriers (n = 14)	TGT Carriers (n = 4)	TGT Noncarriers (n = 9)	TGT Carriers (n = 6)
AUC(0–∞)_bup (ng·h/ml)
Basal	869±63	924±73	1186±100b	1247±161	0.004
Induced	800±99	898±51	1175±81b	1194±90	0.002
% differencee	7.9±0.8	2.8±0.5	2.2±0.8	1.0±0.8	0.229
AU C(0–∞)_hyd (ng·h/ml)
Basal	12,484±1239	12,057±1100	11,485±1499	8844±822c	0.044
Induced	16,759±1624	14,078±676	14,030±1891	11,029±1225c	0.021
% differencee	32.5±6.5*	18.1±5.2a	24.9±9.1*	24.4±7.5	0.048
AUC_hyd/AUC_bup
Basal	14.5±1.5	13.9±1.1	9.7±1.0b	7.6±1.0a , c	0.000
Induced	19.1±1.9	18.6±2.7	11.6±1.1b	9.1±1.5c	0.000
% differencee	34.8±7.1*	30.1±6.7*	23.2±7.0	17.1±9.5a	0.012

^*p<0.01, paired t test between the basal and induced states.

^ap<0.05, Wilcoxon rank-sum test for the NR1I2 groups within each CYP2B6 genotype group.

^bp<0.05, Wilcoxon rank-sum test for the CYP2B6 groups with TGT noncarriers.

^cp<0.05, Wilcoxon rank-sum test for the CYP2B6 groups with TGT carriers.

^dWilcoxon rank-sum test for the CYP2B6 groups; p<0.05 is indicated in bold.

^e% difference represents the percent difference between basal and induced state, calculated as an absolute of 100×(induced-basal)/basal.